Protagenic Therapeutics, Inc. ew (OTC:PTIX)
| Market Cap | $687.88K-83.3% |
| Revenue (ttm) | $0+100.0% |
| Net Income | $5.66M+163.5% |
| EPS | $3.05+163.1% |
| Shares Out | 1.81M |
| PE Ratio | 0.12 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Dec 5, 2005 |
| Volume | 15,513 |
| Open | $0.40 |
| Previous Close | $0.42 |
| Day's Range | $0.35 - $0.48 |
| 52-Week Range | $0.13 - $2.38 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 3, 2027 |
About PTIX
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Protagenic Therapeutics, Inc. ew Stock Analysis — InsiderScore
Protagenic Therapeutics, Inc. ew scored higher than 37% of companies evaluated by InsiderBuying, and ranked 46th out of 99 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Protagenic Therapeutics, Inc. ew bought $23.8K of stock across 3 purchases in the last 90 days, the largest of them $13.0K.
The average purchase added about 30% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 3, 2027Earnings report
$PTIX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PTIX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PTIX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PTIX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PTIX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PTIX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from PTIX’s recent data — informational, not investment advice
